Loading
mRECIST measures only the living, blood-supplied part of a liver cancer on scans, because treatments such as chemoembolisation can kill a tumour without shrinking it.
WHO criteria underestimated response in hepatocellular carcinoma, so an EASL panel amended them in 2000 to count treatment-induced necrosis. RECIST measures shrinkage, which can mislead after targeted drugs or treatments given into the liver. In 2008 an AASLD panel applied the idea of viable tumour, the part that takes up contrast in the arterial phase, to amend RECIST; Lencioni and Llovet (Seminars in Liver Disease 2010) summarised these rules as modified RECIST and noted they still needed checking against pathology of removed livers.
mRECIST for liver cancer is not the same as the modified RECIST used for pleural mesothelioma or thymic tumours, which change how the tumour is measured rather than what is measured.
Showing the technology this term belongs to: CT (computed tomography).
Shares LI-RADS (Liver Imaging Reporting and Data System), BCLC staging, Hepatocellular carcinoma.
Shares LI-RADS (Liver Imaging Reporting and Data System), BCLC staging, Hepatocellular carcinoma.
Shares RECIST, CT (computed tomography), MRI.
Shares BCLC staging, Hepatocellular carcinoma.
Shares RECIST, CT (computed tomography), MRI.
Shares RECIST, CT (computed tomography).
Shares BCLC staging, Hepatocellular carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/